157 related articles for article (PubMed ID: 16305582)
1. Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-uracil as an in vivo probe.
Ito S; Kawamura T; Inada M; Inoue Y; Hirao Y; Koga T; Kunizaki J; Shimizu T; Sato H
Br J Clin Pharmacol; 2005 Dec; 60(6):584-93. PubMed ID: 16305582
[TBL] [Abstract][Full Text] [Related]
2. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.
Mattison LK; Fourie J; Hirao Y; Koga T; Desmond RA; King JR; Shimizu T; Diasio RB
Clin Cancer Res; 2006 Jan; 12(2):549-55. PubMed ID: 16428499
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic modelling of [2-13C]uracil metabolism in normal and DPD-deficient dogs.
Inada M; Hirao Y; Koga T; Itose M; Kunizaki J; Shimizu T; Sato H
Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1205-9. PubMed ID: 17065092
[TBL] [Abstract][Full Text] [Related]
4. Relationships among plasma [2-(13)C]uracil concentrations, breath (13)CO(2) expiration, and dihydropyrimidine dehydrogenase (DPD) activity in the liver in normal and dpd-deficient dogs.
Inada M; Hirao Y; Koga T; Itose M; Kunizaki J; Shimizu T; Sato H
Drug Metab Dispos; 2005 Mar; 33(3):381-7. PubMed ID: 15616154
[TBL] [Abstract][Full Text] [Related]
5. (13)C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients.
Cunha-Junior GF; De Marco L; Bastos-Rodrigues L; Bolina MB; Martins FL; Pianetti GA; Cesar IC; Coelho LG
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1273-82. PubMed ID: 24101147
[TBL] [Abstract][Full Text] [Related]
6. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
[TBL] [Abstract][Full Text] [Related]
7. LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients.
Büchel B; Rhyn P; Schürch S; Bühr C; Amstutz U; Largiadèr CR
Biomed Chromatogr; 2013 Jan; 27(1):7-16. PubMed ID: 22454320
[TBL] [Abstract][Full Text] [Related]
8. [Assay method for uracil, dihydrouracil, 5-fluorouracil and 5-fluoro-5, 6-dihydrouracil by high-performance liquid chromatography].
Nakamura A; Kikuchi K; Ohishi T; Masuike T
Gan To Kagaku Ryoho; 2004 Mar; 31(3):381-6. PubMed ID: 15045945
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
10. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.
Jiang H; Lu J; Ji J
Br J Pharmacol; 2004 Feb; 141(4):616-23. PubMed ID: 14744810
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an oral uracil loading test to identify DPD-deficient patients using a limited sampling strategy.
van Staveren MC; van Kuilenburg AB; Guchelaar HJ; Meijer J; Punt CJ; de Jong RS; Gelderblom H; Maring JG
Br J Clin Pharmacol; 2016 Mar; 81(3):553-61. PubMed ID: 26551538
[TBL] [Abstract][Full Text] [Related]
13. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
[TBL] [Abstract][Full Text] [Related]
14. Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes.
Sparidans RW; Bosch TM; Jörger M; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jul; 839(1-2):45-53. PubMed ID: 16513432
[TBL] [Abstract][Full Text] [Related]
15. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; Dołegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
16. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
Thomas HR; Ezzeldin HH; Guarcello V; Mattison LK; Fridley BL; Diasio RB
Pharmacogenet Genomics; 2007 Nov; 17(11):973-87. PubMed ID: 18075467
[TBL] [Abstract][Full Text] [Related]
17. Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
Galarza AF; Linden R; Antunes MV; Hahn RZ; Raymundo S; da Silva AC; Staggemeier R; Spilki FR; Schwartsmann G
Clin Biochem; 2016 Nov; 49(16-17):1221-1226. PubMed ID: 27399164
[TBL] [Abstract][Full Text] [Related]
18. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
[TBL] [Abstract][Full Text] [Related]
19. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients.
Fleming RA; Milano G; Thyss A; Etienne MC; Renée N; Schneider M; Demard F
Cancer Res; 1992 May; 52(10):2899-902. PubMed ID: 1581906
[TBL] [Abstract][Full Text] [Related]
20. [Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil].
Yamada Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():37-41. PubMed ID: 16897970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
